ClinicalTrials.gg
CompletedNCT05728684Updated Nov 18, 2026

Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease

An interventional study of CM310 in IgG4 Related Disease, sponsored by Beijing Friendship Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Beijing Friendship Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now CompletedFirst site in China+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Immunoglobulin G4-Related Disease with a site in China — 24 open to participants now, 28 under way, 5 of them phase 3. Immunoglobulin G4-Related Disease · China.

Enrollment
29th of 37
20 · median 58
Started
2023
with 5 others
No phase
11 of 41
7 open now
Registered
15th of 41
by date
Lead sponsor
1 of 41
Beijing Friendship Hospital

Among the 41 studies in Immunoglobulin G4-Related Disease with a site in China, this one is the 29th largest by enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2023, is one of 11 with no phase, and was the 15th registered.

Immunoglobulin G4-Related Disease

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

24 of the 41 studies in Immunoglobulin G4-Related Disease with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Immunoglobulin G4-Related Disease with a site in China, or all of them as a file.
02

Study summary

This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.

Read the detailed description

This study includes three stages: screening period, treatment period and safety follow-up period.

03

Conditions studied

  • IgG4 Related Disease

Keywords

  • CM310
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years, male and female.
  • With IGG4-related disease.

Exclusion criteria

Exclusion Criteria:

  • Inoculate within 4 weeks before screening.
  • Treponema pallidum antibody positive in screening period.
  • Active hepatitis in screening period.
  • With a history of solid organ or cell transplantation within 6 months before screening.
  • With other medical or non-medical conditions that are not suitable for the study by the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    CM310

    CM310, subcutaneous

    Biological: CM310

Interventions

06

What researchers measure

Primary outcomes

  1. Response rate

    Response rate after administration for 12 weeks

    Time frame: up to week 12

Secondary outcomes

  1. Change in RI and Physician Global Assessment (PGA) scores

    Change in RI and Physician Global Assessment (PGA) scores from baseline

    Time frame: up to week 12

  2. Rescue therapy rate

    Rescue therapy was defined as the initiation of any additional immunosuppressive or glucocorticoid treatment beyond the protocol-specified regimen due to insufficient efficacy or disease flare. The type and dose of rescue therapy will be recorded.

    Time frame: From baseline to Week 12

07

Study locations

1 site
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality 100050, China
08

References and documents

Individual participant data

Plan to share: No — Data are not available for sharing due to patient privacy and institutional ethical restrictions.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2023 to primary completion in Feb 2024, 12 months.

Completion moved once since we started tracking on Sep 25, 2026: Feb 2024 → Apr 2024, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2023
First posted
Feb 15, 2023
StartActual
Feb 20, 2023
Primary completionActual
Feb 26, 2024
CompletionActual
Apr 23, 2024was Feb 2024
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 18, 2026
Sites
1 site added — first site in China
Show site
  • Beijing Friendship Hospital, Capital Medical University · Beijing, China
Nov 18, 2026
Start date
Feb 28, 2023→Feb 20, 2023 (actual)
Nov 18, 2026
Primary completion
Feb 28, 2024→Feb 26, 2024 (actual)
Nov 18, 2026
Study completion
Feb 28, 2024→Apr 23, 2024 (actual)
Nov 18, 2026
Secondary outcomes
2 added
What changed in the outcomes
  • AddedChange in RI and Physician Global Assessment (PGA) scoresTime frame: up to week 12
  • AddedRescue therapy rateTime frame: From baseline to Week 12
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Status unknown→Completed
    1 site added — first site in China
    Show site
    • Beijing Friendship Hospital, Capital Medical University · Beijing, China
    Start date Feb 28, 2023→Feb 20, 2023 (now actual)
    Primary completion Feb 28, 2024→Feb 26, 2024 (now actual)
    Study completion Feb 28, 2024→Apr 23, 2024 (now actual)
    Secondary outcomes 2 added
    What changed in the outcomes
    • AddedChange in RI and Physician Global Assessment (PGA) scoresTime frame: up to week 12
    • AddedRescue therapy rateTime frame: From baseline to Week 12
    + 4 other changes: identifiers, verification date, conditions and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05728684
Responsible party
Liu Yanying (Deputy Director of Rheumatology Department, Beijing Friendship Hospital) — Principal investigator
First posted
Feb 15, 2023
Start date
Feb 20, 2023
Primary completion
Feb 26, 2024
Completion
Apr 23, 2024
Last update
Nov 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion